Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin

1. Micallef JM, Kaldor JM and Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. 2006 J. Viral Hepatitis, 13:34-41.Search in Google Scholar

2. Verna EC, Brown RS Jr. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006;10(4):919-40.10.1016/j.cld.2006.08.012Search in Google Scholar

3. Civan J, Hann HW. Hepatitis C Virus Mediated Hepatocellular Carcinoma: A Focused Review for a Time of Changing Therapeutic Options. N A J Med Sci. 2014;7(1):8-16.10.7156/najms.2014.0701008Search in Google Scholar

4. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553-562.10.1038/nrgastro.2013.107Search in Google Scholar

5. Kiprijanovska S, Davalieva K, Novevski P, et al. Prevalence of hepatitis C virus genotypes in risk groups in the Republic of Macedonia: a 5 years survey. J Med Virol 2013;85(12):2072-8.10.1002/jmv.23706Search in Google Scholar

6. Samreen B, Khaliq S, Ashfag UA, et al. Hepatitis C virus entry: role of host and viral factors. Infect Genet Evol. 2012; 12(8):1699-709.10.1016/j.meegid.2012.07.010Search in Google Scholar

7. Dzekova-Vidimliski P, Nikolov I, Matevska-Geshkovska N, et al. Genetic predictors of the response to the treatment of hepatitis C virus infection. Bosn J Basic Med Sci 2015; 15(4):55-9.10.17305/bjbms.2015.632Search in Google Scholar

8. Alberti A. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? Liver Int 2009; 29 (Suppl 1): 15-18.10.1111/j.1478-3231.2008.01945.xSearch in Google Scholar

9. Yu JW, Sun LJ, Liu W, et al. Hepatitis C virus core protein induces hepatic metabolism disorders through down-regulation of the SIRT1-AMPK signaling pathway. Int J Infect Dis 2013; 17(7):e539-45.10.1016/j.ijid.2013.01.027Search in Google Scholar

10. Bugianesi E, Salamone F, Negro F. The interaction of metabolic factors with HCV infection:does it matter? Journal of hepatology, 2012; 56(1)S56-S65.10.1016/S0168-8278(12)60007-5Search in Google Scholar

11. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-641.10.1053/j.gastro.2004.12.04915765399Search in Google Scholar

12. Grassi G, Di Caprio G, Fimia et al. Hepatitis C virus relies on lipoproteins for its life cycle. World J Gastroenterol 2016; 22(6): 1953-1965.10.3748/wjg.v22.i6.1953Search in Google Scholar

13. Bassendine MF, Sheridan DA, Bridge SH, et al. Lipids and HCV. Semin Immunopathol. 2013; 35: 87-100.10.1007/s00281-012-0356-2Search in Google Scholar

14. Schaffler A, Muller-Ladner U, Scholmerich J, et al. Role of adipose tissue as an inflamatory organ in human disease. Endocr Rev 2006; 27: 449-67.10.1210/er.2005-0022Search in Google Scholar

15. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.10.1001/jama.285.19.2486Search in Google Scholar

16. Wu Q, Zhan FY, Chen EQ, et al. Predictors of Pegylated Interferon Alpha and Ribavirin Efficacy and Long-Term Assessment of Relapse in Patients With Chronic Hepatitis C: A One-Center Experience From China.Hepatitis Monthly. 2015;15(6):e28836.10.5812/hepatmon.15(6)2015.28836Search in Google Scholar

17. Chuang W-L, Yu M-L. Host factors determining the efficacy of hepatitis C treatment. Journal of Gastroenterology. 2013;48(1):22-30.10.1007/s00535-012-0669-x369843523104468Search in Google Scholar

18. Roeder C, Jordan S, Schulze Zur Wiesch J, et al. Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection. World J Gastroenterol. 2014;20(31):10984-10993.10.3748/wjg.v20.i31.10984413847925152602Search in Google Scholar

19. Frei P, Leucht AK, Held U, et al; Swiss Hepatitis C Cohort Study Group. Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients. Liver Int.2014 Apr;34(4):551-7.10.1111/liv.1227924034338Search in Google Scholar

20. Nishikawa H, Iguchi E, Koshikawa Y, et al. The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients. BMC Res Notes. 2012;5:135.10.1186/1756-0500-5-135331786622405406Search in Google Scholar

21. Dimova RB, Zeremski M, Jacobson IM, et al. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta- analysis. Clin Infect Dis. 2013; 56(6):806-16.10.1093/cid/cis1007358235423223596Search in Google Scholar

22. Dore G, Hellard M, Matthews G, et al. Effective treatment of injecting drug users with recently acquired Hepatitis C virus infection. Gastroenterology. 2010;138(1):123.10.1053/j.gastro.2009.09.019281339119782085Search in Google Scholar

23. Hellard M, Sacks-Davis R, Gold J. Hepatitis C Treatment for Injection Drug Users: A Review of the Available EvidenceClin Infect Dis. (2009) 49 (4): 561-573.10.1086/60030419589081Search in Google Scholar

24. Kurelac I, Papic N, Sakoman S, et al. Intravenous Drug Users Can Achieve a High Sustained Virological Response Rate: experience From Croatian Reference Center for Viral Hepatitis. Hepat Mon. 2011;11(12):986-992.10.5812/kowsar.1735143X.4216328203222368683Search in Google Scholar

25. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245-64.10.1016/j.jhep.2011.02.02321371579Search in Google Scholar

26. Ghany MG, Nelson DR, Strader DB, et al. American Association for Study of Liver D. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433-44.10.1002/hep.24641322984121898493Search in Google Scholar

27. Izumi N, Asahina Y, Kurosaki M. Predictors of Virological Response to a Combination Therapy with Pegylated Interferon Plus Ribavirin Including Virus and Host Factors. Hepatitis Research and Treatment. 2010;2010:703602.10.1155/2010/703602300399521188200Search in Google Scholar

28. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004;40:484-490.10.1016/j.jhep.2003.11.00415123364Search in Google Scholar

29. Fierro NA, Gonzalez-Aldaco K, Torres-Valadez R, et al. Immunologic, metabolic and genetic factors in hepatitis C virus infection. World J Gastroenterol 2014; 20(13): 3443-3456.10.3748/wjg.v20.i13.3443397451124707127Search in Google Scholar

30. Jonsson JR, Barrie HD, O’Rourke P, et al. Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology 2008 Jul;48(1):80-7.10.1002/hep.2231118571785Search in Google Scholar

31. Popescu CI, Riva L, Vlaicu O, et al. Hepatitis C Virus Life Cycle and Lipid Metabolism. Biology 2014, 3(4), 892-921.10.3390/biology3040892428051625517881Search in Google Scholar

32. Jung HJ, Kim YS, Kim SG, et al. The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients. Clinical and molecular hepatology 2014; 20(1): 38-46.10.3350/cmh.2014.20.1.38399232824757657Search in Google Scholar

33. Ramcharran D, Wahed AS, Conjeevaram HS, et al. Virahep-C Study Group. Associations Between Serum Lipids and Hepatitis C Antiviral Treatment Efficacy. Hepatology 2010;52(3):854-63.10.1002/hep.23796293882720690192Search in Google Scholar

34. Angelico F, Francioso S, Del Ben M, et al. Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients. Aliment Pharmacol Ther 2009;30, 444-451.10.1111/j.1365-2036.2009.04055.x19493257Search in Google Scholar

35. Negro F. Steatosis and insulin resistance in response to treatment of chronic hepatitis C. Journal of Viral Hepatitis, 2012, 19 (Suppl. 1), 42-47.10.1111/j.1365-2893.2011.01523.x22233413Search in Google Scholar

36. Vespasiani-Gentilucci U, Gallo P, De Vincentis A, et al. A. Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis. World Journal of Gastroenterology : WJG. 2014;20(11):2825-2838.10.3748/wjg.v20.i11.2825396198724659875Search in Google Scholar

37. Enjoji M, Kohjima M, Kotoh K, et al. Metabolic Disorders and Steatosis in Patients with Chronic Hepatitis C: Metabolic Strategies for Antiviral Treatments. International Journal of Hepatology, 2012, Article ID 264017, 7 pages, 2012.10.1155/2012/264017337312422701799Search in Google Scholar

38. Negro F. Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases. Journal of Hepatology 2014 vol. 61 j S69-S7810.1016/j.jhep.2014.08.00325443347Search in Google Scholar

39. Laurito MP, Parise ER. Association between insulin resistance and sustained virologic response in hepatitis C treatment, genotypes 1 versus 2 and 3: systematic literature review and meta-analysis. Braz J Infect Dis . 2013; 17( 5 ): 555-563.10.1016/j.bjid.2013.02.00924055394Search in Google Scholar

40. Kiran Z, Zuberi BF, Anis D, et al. Insulin resistance in non-diabetic patients of chronic Hepatitis C. Pak J Med Sci 2013;29(1):201-204. Search in Google Scholar